IDiyas

For the Inventor, By the Inventor

Chertswood, Australia

Christopher Liddle

USPTO Granted Patents = 14

 


Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • New South Wales, AU (2009 - 2012)
  • Chatswood, AU (2006 - 2015)
  • Tura Beach, AU (2018 - 2019)
  • Chertswood, AU (2018 - 2022)

Company Filing History:

goldMedal12 out of 267 
 
The University of Sydney Commercial Development & Industry Partnerships
 patents
silverMedal8 out of 576 
 
The Salk Institute for Biological Studies
 patents
bronzeMedal1 out of 3 
 
The University of Syndey
 patents
where one patent can have more than one assignee

Years Active: 2006-2022

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):
1. 11440889 - Analogs of fexaramine and methods of making and using (2022-09-13),
2. 10815203 - Analogs of fexaramine and methods of making and using (2020-10-27),
3. 10450277 - Analogs of fexaramine and methods of making and using (2019-10-22),
4. 10301268 - Analogs of fexaramine and methods of making and using (2019-05-28),
5. 10238667 - Vitamin D receptor/SMAD genomic circuit gates fibrotic response (2019-03-26),
6. 10077268 - FXR agonists and methods for making and using (2018-09-18),
7. 9872866 - Vitamin D receptor/SMAD genomic circuit gates fibrotic response (2018-01-23),
8. 9029336 - Xenobiotic related induction of gene expression (2015-05-12),
9. 8629318 - Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation (2014-01-14),
10. 8318708 - Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis (2012-11-27),
11. 8088968 - Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation (2012-01-03),
12. 7638614 - Xenobiotic related induction of gene expression (2009-12-29),
13. 7531712 - P450 gene regulation (2009-05-12),
14. 6984489 - Cytochrome P450 transcriptional enhancer nucleic acid molecule (2006-01-10),

Title: The Innovative Journey of Inventor Christopher Liddle

Introduction:

Christopher Liddle, a talented inventor hailing from Chertswood, AU, has left an indelible mark in the field of pharmaceuticals with his groundbreaking patents and innovative compounds.

Latest Patents:

Liddle's latest patents revolve around analogs of fexaramine, showcasing his prowess in developing novel compounds for treating metabolic disorders and inflammation. These compounds activate FXR receptors in the intestines, offering new avenues for addressing health challenges.

Career Highlights:

With an impressive portfolio of 14 patents, Christopher Liddle has demonstrated his commitment to advancing medical science. His dedication to research and development has led to significant breakthroughs in the field of pharmaceuticals.

Collaborations:

During his career, Liddle has worked with esteemed institutions such as The University of Sydney and The Salk Institute for Biological Studies. Collaborating with experts like Ronald Mark Evans and Michael Downes has further enriched his innovative endeavors.

Conclusion:

Christopher Liddle's contributions to the world of pharmaceuticals exemplify a passion for innovation and a drive to make a meaningful impact on human health. His relentless pursuit of novel solutions underscores the importance of visionary inventors in shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…